Identical ph III trials reveal different results

By Melissa Fassbender contact

- Last updated on GMT

The studies included more than 2,100 people across 28 countries. (Image: iStock)
The studies included more than 2,100 people across 28 countries. (Image: iStock)

Related tags: Monoclonal antibodies, Clinical trial

Genentech, a member of the Roche Group, has announced top-line results from two phase III studies, which had conflicting results.

The LAVOLTA I-II studies were identical, double-blind, randomized, multi-center, placebo-controlled studies designed to evaluate the efficacy and safety of lebrikizumab – a novel humanized monoclonal antibody designed to treat severe asthma.

Together, the studies included more than 2,100 people across 28 countries.

According to the company’s recent release, one study met its primary endpoint (showing lebrikizumab significantly reduced exacerbations in people with severe asthma); however, the second study did not meet statistical significance.

It is too early to determine why the results of the LAVOLTA I study and LAVOLTA II study are different​,” a Roche spokesperson told Outsourcing-Pharma.com.
The conflicting results highlight the difficulties faced in clinical trials. As such, the company plans on submitting the results for presentation at forthcoming medical meetings after analyzing the data to better understand the results.

We were hopeful these identical studies would confirm the phase II results because there is still a significant unmet need for people with severe asthma​,” said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development at Roche.

These data require further interpretation and analyses are ongoing to better understand the results and determine next steps​.”

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars